Skip to main content

Advertisement

SpringerLink
Log in

Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor α in primary central nervous system lymphoma

  • Clinical–patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

Primary central nervous system lymphomas (PCNSL) are rare tumours occurring in the brain. Their biology and the factors predicting survival are not well known. This study investigated expression of the antiapoptotic protein survivin and platelet-derived growth factor A (PDGF-A) and receptor (PDGFRα) in PCNSL.

Experimental design

A total of 44 patients with histologically confirmed PCNSL treated between 1992 and 2004 were included in this study, and tumour specimens were investigated immunohistochemically for expression of survivin, PDGF-A and PDGFRα. Protein expression and clinical variables were analyzed statistically.

Results

Of the 44 tumours 43(98%) were diffuse large B-cell non-Hodgkin’s lymphomas (NHL) and one was a T-cell NHL. Around 37 (84%) of the examined PCNSL specimens showed expression of survivin, 16 (36%) of PDGF-A and 34 (77%) of PDGFRα. Tumours expressing surviving co-expressed PDGFRα frequently and PDGF-A occasionally. Expression of the above proteins was not predictive for survival in this patient group. Except for age and therapy, no other clinical variables correlated significantly with overall survival.

Conclusions

PCNSL express survivin and PDGFRα in the majority of investigated cases. PDGF-A is expressed less frequently. Immunohistochemical detection of these proteins does not correlate with overall survival and cannot be used as a prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Deangelis LM, Hormigo A, (2004). Treatment of primary central nervous system lymphomaSemin Oncol 3:684–92

    Article  Google Scholar 

  2. Plasswilm L, Herrlinger U, Korfel A, Weller M, Kuker W, Kanz L, Thiel E, Bamberg M, (2002). Primary central nervous system (CNS) lymphoma in immunocompetent patients Ann Hematol 81: 415–423

    Article  PubMed  CAS  Google Scholar 

  3. Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O’Reilly SE, Pickles T, Sehn L, Connors JM, (2005).The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer AgencyCancer 103: 1008–1017

    Article  PubMed  Google Scholar 

  4. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT (2003). BCL-6 expression predicts improved survival in patients with primary central nervous system lymphomaClin Cancer Res 9: 1063–1069

    PubMed  CAS  Google Scholar 

  5. Alizadeh AA, Eisen MB, Davis RE, et al, (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403:503–511

    Article  PubMed  CAS  Google Scholar 

  6. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R, (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes N Engl J Med 350: 1828–1837

    Article  PubMed  CAS  Google Scholar 

  7. Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R, (2003). Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07 J Clin Oncol 21: 1044–1049

    Article  PubMed  CAS  Google Scholar 

  8. Bataille B, Delwail V., Menet E, Vandermarq P, Ingrand P, Wager M, Guy G, Lapierre F, (2000). Primary intracerebral malignant lymphoma: report of 248 cases J Neurosurg 92: 261–266

    Article  PubMed  CAS  Google Scholar 

  9. Deveraux QL, Reed JC, (1999). IAP family proteins-suppressors of apoptosis Gene Dev 13:239–252

    Article  PubMed  CAS  Google Scholar 

  10. Ambrosini G, Adida C, Altieri DC, (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3: 917–921

    Article  PubMed  CAS  Google Scholar 

  11. Altieri DC, (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy Trends Mol Med 7: 542–547

    Article  PubMed  CAS  Google Scholar 

  12. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NF, Loeffler JS, (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas J Clin Oncol 20: 1063–1068

    Article  PubMed  CAS  Google Scholar 

  13. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A, (2000). High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma Oncogene 19: 617–623

    Article  PubMed  CAS  Google Scholar 

  14. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y, (2001). Expression of survivin in oesophageal cancer: Correlation with the prognosis and response to chemotherapy Int J Cancer 95: 92–95

    Article  PubMed  CAS  Google Scholar 

  15. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N,(1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res 58: 5071–5074

    PubMed  CAS  Google Scholar 

  16. Lu CD, Altieri DC, Tanigawa N, (1998). Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas Cancer Res 58: 1808–1812

    PubMed  CAS  Google Scholar 

  17. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A, (1999). A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers J Clin Oncol 17: 2100–2104

    PubMed  CAS  Google Scholar 

  18. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC, (1999). Tumour content of antiapoptosis molecule survivin and recurrence of bladder cancer N Engl J Med 341: 452–453

    Article  PubMed  CAS  Google Scholar 

  19. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N, (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 6:127–134

    PubMed  CAS  Google Scholar 

  20. Das A, Tan WL, Smith DR, (2003). Expression of the inhibitor of apoptosis protein survivin in benign meningiomas Cancer Lett 193: 217–223

    Article  PubMed  CAS  Google Scholar 

  21. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ, (2000). Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood 96: 1921–1925

    PubMed  CAS  Google Scholar 

  22. Heldin CH, Westermark B, (1999) Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 79: 1283–1316

    PubMed  CAS  Google Scholar 

  23. Konopka G, Bonni A, (2003). Signaling pathways regulating gliomagenesis Curr Mol Med 3: 73–84

    Article  PubMed  CAS  Google Scholar 

  24. Mischel PS, Cloughesy TF,(2003). Targeted molecular therapy of GBM Brain Pathol 13: 52–61

    Article  PubMed  Google Scholar 

  25. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD, (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 60: 5143–5150

    PubMed  CAS  Google Scholar 

  26. Brown RE, Nazmi RK, (2002). The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications Ann Clin Lab Sci 32: 339–351

    PubMed  CAS  Google Scholar 

  27. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A, (2005). Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma Blood 105:4051–4059

    Article  PubMed  CAS  Google Scholar 

  28. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, Sigaux F, Degos L, Altieri DC, Dombret H, (2000). Expression and prognostic significance of survivin in de novo acute myeloid leukaemia Br J Haematol 111: 196–203

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by research grants from: The University of Liverpool (NEDD and NE5B) to NGR, the State Ministry of Culture and Education of Saxony-Anhalt, Germany, to NGR (2794A/0087H), and The Society of Pathologists of Britain and Northern Ireland to PP, JB and NGR.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The Walton Centre for Neurology and Neurosurgery NHS Trust, L9 7LJ, Liverpool, UK

    K. Karabatsou & N.G. Rainov

  2. Department of Neuropathology, The Walton Centre for Neurology and Neurosurgery NHS Trust, L69 3GS, Liverpool, UK

    P. Pal, M. Aguirreburualde, N. Moxam, W. Pinson-Ellis & J. Broome

  3. Centre for Medical statistics and Health Evaluation, University of Liverpool, L69 3GS, Liverpool, UK

    S. Dodd

  4. Department of Oncology, Clatterbridge Cancer Center, Birmingham, Wirra, UK

    B. Haylock

  5. Division of Neurological Sciences, University of Liverpool, L9 7LJ, Liverpool, UK

    N.G. Rainov

  6. Department of Neurological Sciences, The Walton Centre for Neurology and Neurosurgery NHS Trust, University of Liverpool, Lower Lane, L9 7LJ, Liverpool, UK

    N.G. Rainov

Authors
  1. K. Karabatsou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Dodd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Haylock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Aguirreburualde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Moxam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Pinson-Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Broome
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N.G. Rainov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N.G. Rainov.

Additional information

These authors have contributed equally to the study

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karabatsou, K., Pal, P., Dodd, S. et al. Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor α in primary central nervous system lymphoma. J Neurooncol 79, 171–179 (2006). https://doi.org/10.1007/s11060-005-9102-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9102-0

Keywords

Search

Navigation